AMP-PD: Accelerating Medicines Partnership: Parkinson's Disease and Related Disorders

Introduction

Overview

The Accelerating Medicines Partnership: Parkinson's Disease and Related Disorders (AMP-PD) is a National Institutes of Health (NIH)-sponsored program designed to host and share resources related to Parkinson's disease research. The initiative aims to accelerate biomarker discovery and advance the development of disease-modifying therapies["@amppd"].

The program is part of the broader Accelerating Medicines Partnership (AMP), described as a US$360 million NIH-industry collaboration involving multiple pharmaceutical companies and academic institutions["@accelerating"].

Mission

"Collaborating toward biomarker discovery to advance the development of Parkinson's disease therapies"

Introduction

Overview

The Accelerating Medicines Partnership: Parkinson's Disease and Related Disorders (AMP-PD) is a National Institutes of Health (NIH)-sponsored program designed to host and share resources related to Parkinson's disease research. The initiative aims to accelerate biomarker discovery and advance the development of disease-modifying therapies["@amppd"].

The program is part of the broader Accelerating Medicines Partnership (AMP), described as a US$360 million NIH-industry collaboration involving multiple pharmaceutical companies and academic institutions["@accelerating"].

Mission

"Collaborating toward biomarker discovery to advance the development of Parkinson's disease therapies"

Data Types Available

The AMP-PD portal provides access to multiple harmonized data types:

Genomics

• Whole Genome Sequencing (WGS): From whole blood using Illumina XTen, aligned to Human Genome hg38
• Postmortem Sequencing Data: Brain tissue sequencing from deceased donors

Transcriptomics

• RNA-Seq: From whole blood using Illumina NovaSeq, aligned to Gencode v29

Proteomics

• Targeted Proteomics: Olink Explore panels from cerebrospinal fluid (CSF) and plasma
• Untargeted Proteomics: Using Orbitrap Exploris platform

Clinical Data

• Demographics
• Medical history
• MDS-UPDRS scores
• MoCA (Montreal Cognitive Assessment)
• UPSIT (University of Pennsylvania Smell Identification Test)

Single Nucleus Data

• Single nucleus RNA sequencing from postmortem brain tissue

Cohorts

AMP-PD harmonizes data from eight major cohort studies:

| Cohort | Description |
|--------|-------------|
| [PPMI](/datasets/ppmi) | Parkinson's Progression Markers Initiative - longitudinal PD study |
| PDBP | Parkinson's Disease Biomarkers Program |
| BioFIND | Parkinson's Disease Biomarkers Discovery Initiative |
| LBD | Lewy Body Dementia cohort |
| HBS | Harvard Biomarkers Study |
| STEADY-PD3 | Study of Asenapine and Glyburide in PD |
| SURE-PD3 | Safinamide Study |

Additionally, the portal includes Postmortem Brain Cohort data, bringing the total to approximately 10,908 participants.

Key Statistics

• The data portal contains de-identified information from approximately 4,298 Parkinson's patients and healthy control subjects in the unified analysis dataset
• Data is harmonized across multiple cohort studies including PPMI, PDBP, BioFIND, LBD, and others
• Longitudinal Data: Many participants have multiple timepoints enabling longitudinal analysis of disease progression

Data Harmonization Process

AMP-PD employs rigorous data harmonization protocols to ensure cross-cohort compatibility:

Genomics Harmonization

• Alignment Standards: All WGS data aligned to Human Genome hg38 using BWA-MEM
• Variant Calling: GATK best practices for SNP and indel identification
• Quality Control: Strict filtering for coverage depth and variant quality scores
• Harmonized Phenotypes: Unified clinical variables using common data elements (CDEs)

Proteomics Harmonization

• Olink Panels: Standardized protein panels across all cohorts
• Batch Effect Correction: Statistical correction for technical batch effects
• Control Normalization: Protein levels normalized to internal controls

Research Applications

Biomarker Discovery

• α-Synuclein Biomarkers: Development of α-synuclein seeding assays
• Neurofilament Light Chain (NfL): Blood-based marker for neurodegeneration
• Genetic Risk Scores: Polygenic risk scores for PD susceptibility
• Expression Biomarkers: Gene expression signatures distinguishing PD subtypes

Therapeutic Target Validation

• Target Expression: Validation of drug targets in relevant patient tissues
• Clinical Trial Enrichment: Identification of patient subgroups for targeted trials
• Natural History Studies: Understanding disease progression patterns

Genetic Studies

• GWAS Meta-Analysis: Large-scale genome-wide association studies
• Rare Variant Discovery: Identification of rare pathogenic variants
• Gene-Environment Interactions: Analysis of lifestyle factors and genetic risk

Access for Researchers

Registration

Platform Access

• Terra Platform: Cloud-based research workspace ([https://app.terra.bio/](https://app.terra.bio/))
• Google Cloud Platform: BigQuery for untargeted proteomics data
• Researcher Workbench: Pre-configured Jupyter notebooks in R and Python

Available Resources

• Jupyter notebooks that can be cloned and edited
• Example notebooks demonstrating data retrieval methods
• SmartConverter Data Curation tool
• Visualization tools

Related Resources

• [PPMI](/datasets/ppmi) - Parkinson's Progression Markers Initiative
• [BioFIND](/datasets/biofind) - Parkinson's Disease Biomarkers Discovery Initiative (page pending creation)
• [Parkinson's Disease](/diseases/parkinsons-disease) - Parkinson's Disease

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [AMP-PD Knowledge Portal](https://amp-pdrd.org/)
• [Terra Platform](https://app.terra.bio/)
• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving AMP-PD: Accelerating Medicines Partnership: Parkinson's Disease and Related Disorders discovered through SciDEX knowledge graph analysis: